Haleon Boosts US Sales Targeting GLP-1 Side-Effect Products

Haleon reports increased US sales of products addressing side effects of weight-loss drugs like Wegovy and Zepbound. This reflects a growing market for adjunct therapies as GLP-1 usage expands, though the company's specific revenue figures are not detailed. The trend signals a commercial opportunity for consumer health firms tied to the GLP-1 boom.